Reply to "Metalloproteinase 9 as a Biomarker of Progressive Multifocal Leukoencephalopathy Development in Multiple Sclerosis Patients Receiving Natalizumab"
XX
BSO - Titre
Reply: MMP-9 as a biomarker of PML development in MS patients receiving Natalizumab